Despite missing the initial mark, Clene Inc.’s gold nanocrystal therapy for ALS still shows promise. Thursday, the company shared new results from an exploratory analysis showing CNM-Au8 delayed disease progression across key areas for patients. In October 2022, Clene reported that CNM-Au8 did not meet the primary endpoint of slope of change in the HEALEY ALS trial based on the adjusted […]
Newly announced 6-month findings from the HEALEY-ALS Platform trial, the first of its kind for amyotrophic lateral sclerosis (ALS), showed that treatment with CNM-Au8 (Clene Nanomedicine) was tolerable, with several meaningful delays in clinical worsening and increased survival benefit.1 CNM-Au8 is an oral suspension of gold nanocrystals developed to restore neuronal health and function by […]
As biopharma executives sought funding last week at the BIO CEO & Investor Conference, the strategic mindset could be summed up in three words: flexibility, creativity and concession. Seeking a Series C Salt Lake City-based Halia Therapeutics is working to close a $50 million Series C round to drive its lead asset, an NLRP3 inflammasome […]